Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CYTHW
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.22
N/A
NA
vs NA
Q3.22
N/A
NA
vs NA
Q4.22
N/A
-0.45
vs NA
Q1.23
N/A
-0.46
vs NA
Q2.23
N/A
-0.33
vs NA
Q3.23
N/A
-0.29
vs NA
Q4.23
N/A
NA
vs -0.45
Q1.24
N/A
NA
vs -0.46
Q2.24
N/A
NA
vs -0.33
Q3.24
N/A
NA
vs -0.29
Sales Growth
YoY
Current
Estimates
Q4.22
-68%
186.8K vs 585.1K
Q1.23
-22%
152.4K vs 194.9K
Q2.23
-78%
117.1K vs 541.9K
Q3.23
+10%
495.5K vs 452.2K
Q4.23
+67%
311.4K vs 186.8K
Q1.24
+33%
202.4K vs 152.4K
Q2.24
+5%
123.1K vs 117.1K
Q3.24
-53%
233.8K vs 495.5K
Q4.24
+35%
421.5K vs 311.4K
Q1.25
+20%
242.4K vs 202.4K
Return on Equity
QoQ
Q4.22
-655%
-6.55
vs -0.76
Q1.23
+1141%
11.41
vs -6.55
Q2.23
+312%
3.12
vs 11.41
Q3.23
+453%
4.53
vs 3.12
Q4.23
-119%
-1.19
vs 4.53
Q1.24
-712%
-7.12
vs -1.19
Q2.24
+117%
1.17
vs -7.12
Q3.24
+66%
0.66
vs 1.17
Institutionnal Ownership
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
NASDAQ
Relative Strenght
1
Volume Buzz
131%
Earning Acce
No
Dist 52w H.
95%Forecast
564%2025-Revenue
81%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How CYTHW compares to sector?
CYTHW
-1x